Publications by authors named "Nurgul Kilavuz"
Article Synopsis
- Epcoritamab, a bispecific antibody targeting CD3 and CD20, showed promising long-term results as a monotherapy for relapsed or refractory large B-cell lymphoma (LBCL) in the EPCORE NHL-1 study, with a 63.1% overall response rate and a 40.1% complete response rate after a median follow-up of 25.1 months.
- The estimated 24-month progression-free survival (PFS) and overall survival (OS) rates were 27.8% and 44.6%, respectively, with 64.2% of complete responders maintaining their response at that time.
- Most treatment-emergent adverse events were manageable, with cytokine release syndrome
Article Synopsis
- A study evaluated patient-reported outcomes in adults with relapsed or refractory large B-cell lymphoma treated with epcoritamab, a new monotherapy.
- Patients completed assessments to measure quality of life and symptoms, and the results showed significant improvements in their scores over the treatment period.
- The majority of patients expressed satisfaction with the treatment, highlighting its potential effectiveness in enhancing their quality of life.
Article Synopsis
- Epcoritamab is a bispecific antibody that helps T cells attack and kill malignant B cells, showing strong results in treating B-cell non-Hodgkin lymphoma during previous trials.
- In a phase I/II study, patients with relapsed or refractory large B-cell lymphoma received weekly doses of epcoritamab for up to several months to assess its effectiveness.
- Results showed a 63.1% overall response rate and 38.9% complete response rate among 157 patients with manageable side effects, suggesting it is a promising treatment for difficult cases of lymphoma.
Background: Studies suggest that immune checkpoint inhibitors may represent a promising strategy for boosting immune responses and improving the antitumor activity of standard therapies in patients with relapsed/refractory hematologic malignancies.
Aims: Phase 1/2 FUSION NHL 001 was designed to determine the safety and efficacy of durvalumab, an anti-programmed death ligand 1 (PD-L1) antibody, combined with standard-of-care therapies for lymphoma or chronic lymphocytic leukemia (CLL).
Methods And Results: The primary endpoints were to determine the recommended phase 2 dose of the drugs used in combination with durvalumab (durvalumab was administered at the previously recommended dose of 1500 mg every 4 weeks) and to assess safety and tolerability.
Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can increase antitumor efficacy. This study investigated durvalumab, a programmed death-ligand 1 inhibitor, combined with R-CHOP or lenalidomide + R-CHOP (R-CHOP) in newly diagnosed high-risk DLBCL.
View Article and Find Full Text PDFBackground And Objectives: Durvalumab, a human monoclonal antibody targeting programmed cell death ligand 1, has been approved for urothelial carcinoma and stage III non-small cell lung cancer by the US Food and Drug Administration and is being evaluated in various malignancies. The objective of this study was to develop a population-pharmacokinetic model of durvalumab in patients with various hematologic malignancies and to investigate the effects of demographic and disease factors on the pharmacokinetics in this population.
Methods: A total of 1812 concentrations from 267 patients with myelodysplastic syndromes, acute myeloid leukemia, multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma were included in the analysis.